• In the first quarter of 2026, Healthcare Realty Trust reported revenue of US$278.99 million, nearly break-even net income, sharply lower real estate impairments, and affirmed a quarterly dividend of US$0.24 per share alongside board refresh plans.
• Beneath the softer top-line, record leasing activity, almost 7% same-store cash NOI growth, and higher full-year FFO guidance highlighted stronger property-level performance, active portfolio repositioning, and expanding financial flexibility through buybacks, joint ventures, and new funding tools.
• We’ll now examine how raised FFO guidance and record leasing activity shape Healthcare Realty Trust’s existing investment narrative and risk-return profile.

Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

Healthcare Realty Trust Investment Narrative Recap

To own Healthcare Realty Trust, I think you need to believe its medical office portfolio can steadily grow cash flows as outpatient demand rises, while a new management team successfully shifts the business toward tighter operations. The Q1 2026 results, with raised FFO guidance and almost 7% same store cash NOI growth, support the near term catalyst around lease up and redevelopment execution. They do not, however, remove the longer term risk tied to high leverage and refinancing needs.

Among the recent announcements, the sharp reduction in real estate impairments to just US$16,000 stands out alongside stronger leasing and raised FFO guidance. Together, they suggest that the current asset base is stabilizing as the company recycles roughly US$125 million of properties and invests through joint ventures, which matters if you are focused on the catalyst of unlocking the targeted US$50 million of NOI upside from the lease up and redevelopment portfolio.

Yet while property level trends look healthier, investors should still be aware of how HR’s high leverage could interact with...

Healthcare Realty Trust's narrative projects $1.3 billion revenue and $13.0 million earnings by 2029.

Uncover how Healthcare Realty Trust's forecasts yield a $19.18 fair value, in line with its current price.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community span roughly US$19.18 to US$29.81 per share, showing a wide band of expectations. When you set those side by side with HR’s raised FFO guidance and record leasing momentum, it underlines how differently people weigh the upside from its outpatient-focused portfolio against the balance sheet and execution risks.

Explore 2 other fair value estimates on Healthcare Realty Trust - why the stock might be worth as much as 52% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Healthcare Realty Trust research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Healthcare Realty Trust research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Healthcare Realty Trust's overall financial health at a glance.

Contemplating Other Strategies?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 48 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.